Kuemmel S, Harper-Wynne C, Park YH, Franke F, et al. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the
efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab
and trastuzumab for subcutaneous injection in patients with previously untreated
HER2-po BMC Cancer 2024;24:641.
PMID: 38789924
![]() |
![]() |
![]() |